This CPB has been revised to state that (i) Feraheme (ferumoxytol) is indicated for use in the treatment of iron deficiency anemia in persons with chronic kidney disease, and (ii) intravenous iron therapy is considered experimental and investigational for the treatment of restless legs syndrome.